Position paper on screening for breast cancer by the European Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey

Abstract

EUSOBI and 30 national breast radiology bodies support mammography for population-based screening, demonstrated to reduce breast cancer (BC) mortality and treatment impact. According to the International Agency for Research on Cancer, the reduction in mortality is 40 % for women aged 50–69 years taking up the invitation while the probability of false-positive needle biopsy is <1 % per round and overdiagnosis is only 1–10 % for a 20-year screening. Mortality reduction was also observed for the age groups 40–49 years and 70–74 years, although with “limited evidence”. Thus, we firstly recommend biennial screening mammography for average-risk women aged 50–69 years; extension up to 73 or 75 years, biennially, is a second priority, from 40–45 to 49 years, annually, a third priority. Screening with thermography or other optical tools as alternatives to mammography is discouraged. Preference should be given to population screening programmes on a territorial basis, with double reading. Adoption of digital mammography (not film-screen or phosphor-plate computer radiography) is a priority, which also improves sensitivity in dense breasts. Radiologists qualified as screening readers should be involved in programmes. Digital breast tomosynthesis is also set to become “routine mammography” in the screening setting in the next future. Dedicated pathways for high-risk women offering breast MRI according to national or international guidelines and recommendations are encouraged.Key points• EUSOBI and 30 national breast radiology bodies support screening mammography.• A first priority is double-reading biennial mammography for women aged 50–69 years.• Extension to 73–75 and from 40–45 to 49 years is also encouraged.• Digital mammography (not film-screen or computer radiography) should be used.• DBT is set to become “routine mammography” in the screening setting in the next future.

Designing a resource‐stratified, phased implementation strategy for breast health care services in India

“…The objectives of the national breast health program is population‐based screening of all women aged 30 to 65 years for breast cancer to enable early detection and management 12 . Although most guidelines on population‐based screening for breast cancers recommend starting no earlier than age 40 years, 13,14 the Indian national guideline recommends starting at age 30 years to ensure uniformity across the 3 cancers included in the national program (cervical, breast, and oral), which would facilitate operational feasibility.…”

Potential role of abbreviated MRI for breast cancer screening in an academic medical center

“…Legislation requiring patient notification of breast tissue density and the associated increased risk of breast cancer has resulted in an increased demand for supplemental screening . Supplemental screening with breast MRI or ultrasound is now commonly used in high‐risk populations to identify early stage cancers, with reported cancer detection rates (CDR) of 14.7/1000 and 3.7/1000 women screened, respectively …”

Künstliche Intelligenz in der Mammadiagnostik

“…In den mittlerweile nahezu nahtlos in der westlichen Welt eingesetzten Screening-Programmen spielt die Mammographie eine zentrale Rolle [21]. Die Mammographie bietet insbesondere bei geringer Brustdichte eine hervorragende diagnostische Genauigkeit zur Detektion von Brustkrebs.…”